JARI Pharmaceutical Co.

Xinpu, China

JARI Pharmaceutical Co.

Xinpu, China
SEARCH FILTERS
Time filter
Source Type

Wang X.-J.,The 716th Institute of CSIC | Wang X.-J.,JARI Pharmaceutical Co. | Wu J.,Wuhan Bioengineering Institute
Journal of Chemical and Pharmaceutical Research | Year: 2014

A new series of bis-benzimidazole derivatives was designed and synthesized. In vitro cytotoxity evaluation showed that these compounds exhibited high activity against the selected tumor cells. Among them, compound 8 owned the best potential, its IC50 values being 0.58 μM (mononuclear tumor cell line (U937)) and 0.56 μM (cervical cancer cell (Hela)), respectively. Molecular modeling, fluorescence and viscometry study showed that compound 8could bind into the minor groove of DNA. © 2014, Journal of Chemical and Pharmaceutical Research. All rights reserved.


Wang X.-J.,716th Institute of CSIC | Wang X.-J.,JARI Pharmaceutical Co. | Yang M.-L.,JARI Pharmaceutical Co. | Zhang L.-P.,JARI Pharmaceutical Co. | And 7 more authors.
Chinese Chemical Letters | Year: 2014

A new series of bis-benzimidazole derivatives were designed and synthesized. In vitro cytotoxicity evaluation showed that these compounds exhibited high activity against the selected tumor cells. Among them, compound 9 owned the best potential, its IC50 values being 5.95 μmol/L (mononuclear tumor cell line (U937)) and 5.58 μmol/L (cervical cancer cell (HeLa)). Fluorescence and UV-vis studies showed that compound 9 could bind into the minor groove of DNA. © 2014 Ming-Li Yang.

Loading JARI Pharmaceutical Co. collaborators
Loading JARI Pharmaceutical Co. collaborators